Health-related Quality of Life and Clinical Outcome After Radiotherapy of Patients with Intracranial Meningioma

Overview

Journal Sci Rep

Specialty Science

Date 2022 Nov 17

PMID 36396802

Authors

Dominik Lisowski

Jannik Tromel

Paul Lutyj

Victor Lewitzki

Philipp E Hartrampf

Bulent Polat

Michael Flentje

Jorg Tamihardja

Affiliations

Soon will be listed here.

Abstract

This retrospective, single-institutional study investigated long-term outcome, toxicity and health-related quality of life (HRQoL) in meningioma patients after radiotherapy. We analyzed the data of 119 patients who received radiotherapy at our department from 1997 to 2014 for intracranial WHO grade I-III meningioma. Fractionated stereotactic radiotherapy (FSRT), intensity modulated radiotherapy (IMRT) or radiosurgery radiation was applied. The EORTC QLQ-C30 and QLQ-BN20 questionnaires were completed for assessment of HRQoL. Overall survival (OS) for the entire study group was 89.6% at 5 years and 75.9% at 10 years. Local control (LC) at 5 and 10 years was 82.4% and 73.4%, respectively. Local recurrence was observed in 22 patients (18.5%). Higher grade acute and chronic toxicities were observed in seven patients (5.9%) and five patients (4.2%), respectively. Global health status was rated with a mean of 59.9 points (SD 22.3) on QLQ-C30. In conclusion, radiotherapy resulted in very good long-term survival and tumor control rates with low rates of severe toxicities but with a deterioration of long-term HRQoL.

Citing Articles

Cook W, Khalil F, Gillespie C, Helmy A Neurosurg Rev. 2025; 48(1):268.

PMID: 40011234 PMC: 11865157. DOI: 10.1007/s10143-025-03420-5.

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.

Wang J, Landry A, Raleigh D, Sahm F, Walsh K, Goldbrunner R Neuro Oncol. 2024; 26(10):1742-1780.

PMID: 38695575 PMC: 11449035. DOI: 10.1093/neuonc/noae082.

San A, Rahman R, Sanmugananthan P, Dube M, Panico N, Ariwodo O Cancers (Basel). 2023; 15(19).

PMID: 37835374 PMC: 10571784. DOI: 10.3390/cancers15194680.

Long Term Outcome and Quality of Life of Intracranial Meningioma Patients Treated with Pencil Beam Scanning Proton Therapy.

Krcek R, Leiser D, Garcia-Marqueta M, Bolsi A, Weber D Cancers (Basel). 2023; 15(12).

PMID: 37370709 PMC: 10296362. DOI: 10.3390/cancers15123099.

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.

Gregory G, Islim A, Hannan C, Jones A, Hammerbeck-Ward C, Rutherford S Neurooncol Adv. 2023; 5(Suppl 1):i94-i104.

PMID: 37287576 PMC: 10243851. DOI: 10.1093/noajnl/vdac127.

References

Combs S, Schulz-Ertner D, Debus J, von Deimling A, Hartmann C . Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys. 2010; 81(5):1415-21. DOI: 10.1016/j.ijrobp.2010.07.039. View

Nolte S, Liegl G, Petersen M, Aaronson N, Costantini A, Fayers P . General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2018; 107:153-163. DOI: 10.1016/j.ejca.2018.11.024. View

Rogers C, Won M, Vogelbaum M, Perry A, Ashby L, Modi J . High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2019; 106(4):790-799. PMC: 7117785. DOI: 10.1016/j.ijrobp.2019.11.028. View

Weber D, Ares C, Villa S, Peerdeman S, Renard L, Baumert B . Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018; 128(2):260-265. DOI: 10.1016/j.radonc.2018.06.018. View

Konglund A, Rogne S, Lund-Johansen M, Scheie D, Helseth E, Meling T . Outcome following surgery for intracranial meningiomas in the aging. Acta Neurol Scand. 2012; 127(3):161-9. DOI: 10.1111/j.1600-0404.2012.01692.x. View

King M . The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996; 5(6):555-67. DOI: 10.1007/BF00439229. View

Bitterlich C, Vordermark D . Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. Oncol Lett. 2017; 14(2):1841-1846. PMC: 5529906. DOI: 10.3892/ol.2017.6310. View

Stafford S, Pollock B, Foote R, Link M, Gorman D, Schomberg P . Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2002; 49(5):1029-37; discussion 1037-8. DOI: 10.1097/00006123-200111000-00001. View

Minniti G, Amichetti M, Maurizi Enrici R . Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol. 2009; 4:42. PMC: 2768735. DOI: 10.1186/1748-717X-4-42. View

10.

Tanzler E, Morris C, Kirwan J, Amdur R, Mendenhall W . Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 79(2):508-13. DOI: 10.1016/j.ijrobp.2009.11.032. View

11.

Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J . Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005; 61(3):809-16. DOI: 10.1016/j.ijrobp.2004.07.669. View

12.

Bondy M, Ligon B . Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996; 29(3):197-205. DOI: 10.1007/BF00165649. View

13.

Rogers C, Perry A, Pugh S, Vogelbaum M, Brachman D, McMillan W . Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol. 2015; 18(4):565-74. PMC: 4799683. DOI: 10.1093/neuonc/nov247. View

14.

Hamm K, Henzel M, Gross M, Surber G, Kleinert G, Engenhart-Cabillic R . Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir. 2008; 69(1):14-21. DOI: 10.1055/s-2007-992138. View

15.

Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

16.

Dolecek T, Dressler E, Thakkar J, Liu M, Al-Qaisi A, Villano J . Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015; 121(14):2400-10. PMC: 5549267. DOI: 10.1002/cncr.29379. View

17.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

18.

Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A . Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 83(3):859-64. DOI: 10.1016/j.ijrobp.2011.08.010. View

19.

Hartrampf P, Hanscheid H, Kertels O, Schirbel A, Kreissl M, Flentje M . Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020; 22:29-32. PMC: 7075763. DOI: 10.1016/j.ctro.2020.03.002. View

20.

Zamanipoor Najafabadi A, Peeters M, Dirven L, Lobatto D, Groen J, Broekman M . Impaired health-related quality of life in meningioma patients-a systematic review. Neuro Oncol. 2017; 19(7):897-907. PMC: 5570251. DOI: 10.1093/neuonc/now250. View